-
Moxifloxacin Workflows for Antibiotic Toxicity
2026-09-15
Build reproducible Moxifloxacin assays that connect DNA gyrase inhibition with cellular viability, retinal ganglion cell responses, and acute metabolic endpoints. This guide combines practical dose-response design, mechanistic controls, and troubleshooting for antibiotic toxicity research.
-
S Tag Peptide: Practical Fusion-Tag Workflow
2026-09-15
S Tag Peptide is a compact, highly soluble fusion tag for recombinant protein detection, antibody-based capture, and protein solubility improvement. This guide covers construct design, aqueous handling, QC, and troubleshooting while clarifying that the peptide is not a standalone ribonuclease reagent and is unsuitable for ethanol-based protocols.
-
Nintedanib in ATRX-Deficient Glioma Research
2026-09-14
Learn how Nintedanib (BIBF 1120) can support genotype-aware glioma assays, RTK/PDGFR inhibitor screening, and combination studies with temozolomide. The workflow emphasizes solubility control, ATRX-stratified comparisons, mechanistic readouts, and practical troubleshooting.
-
Praeruptorin A: Applied Research Workflows
2026-09-14
Praeruptorin A connects inflammation, ferroptosis, cardiomyopathy, and cancer-invasion assays through experimentally testable pathways rather than a single endpoint. This workflow translates its STAT-1/3, DMT1, ERK1/2, and MMP1 biology into practical dosing, controls, troubleshooting, and translational decision points.
-
3X (DYKDDDDK) Peptide: Workflow Guide
2026-09-13
The 3X (DYKDDDDK) Peptide supports competitive elution, sensitive FLAG-fusion detection, and structurally informed protein workflows. This guide connects practical purification and assay decisions with lessons from a recent cryo-EM study of human PSS2.
-
GLI2, WNT, and Prostaglandins in Immunotherapy Resistance
2026-09-12
DeVito et al. identify GLI2 as a mechanistic coordinator linking mesenchymal transformation to WNT ligand production, prostaglandin signaling, and an immunosuppressive tumor microenvironment. The findings connect GLI2 activity with myeloid-derived suppressor cell recruitment, impaired cytotoxic lymphocyte function, and primary or adaptive resistance to anti-PD-1 therapy, providing a rationale for pathway-informed combination studies.
-
Atropo-Enantioselective Suzuki Synthesis: Rhazinilam Analog
2026-09-12
Herrbach and co-workers reported the first application of an asymmetric Suzuki cross-coupling to a biologically relevant axially chiral biaryl target. Screening and optimization of chiral phosphine ligands, particularly binaphthyl ligand 7a, furnished a nonbridged rhazinilam analogue precursor with up to 40% enantiomeric excess, establishing a catalytic route to the biologically relevant atropisomer.
-
NSC-23766: Rac1 Signaling Beyond Phagocytosis
2026-09-11
NSC-23766 is a Rac GTPase inhibitor that can help separate Rac-dependent cytoskeletal events from upstream immune-receptor signaling. This article translates recent CD47–Vav–Rac findings into practical assay design while defining the limits of extending Rac1 pharmacology to cancer and vascular models.
-
2-DG and the Metabolic-Epigenetic NSCLC Frontier
2026-09-11
A translational framework for using 2-Deoxy-D-glucose to interrogate glycolytic dependence, lactate-linked H3K18 lactylation, KRT19-driven senescence escape, and combination strategies in non-small cell lung cancer research.
-
Mubritinib–HSA Recognition: Methods and Findings
2026-09-10
The reference study clarifies how mubritinib interacts with human serum albumin through complementary fluorescence, biochemical, and molecular docking analyses. Its central contribution is linking moderate site I binding and local structural perturbation to inhibition of an HSA esterase-like function, providing a more pharmacologically meaningful view than affinity measurements alone.
-
SAR405: A Vps34 Probe for Nuclear PI3P
2026-09-10
SAR405 is a selective Vps34 inhibitor for dissecting autophagy, vesicle trafficking, and PI3P-dependent signaling. This article develops a compartment-aware assay framework linking Vps34 perturbation to nuclear DNA mismatch repair while distinguishing established evidence from testable hypotheses.
-
Gut Microbial H2S Suppresses GLP-1 in Male Mice
2026-09-09
This Nature Metabolism study identifies Desulfovibrio-derived hydrogen sulfide as a gut-to-host signal that impairs GLP-1 production by intestinal L cells through mitochondrial and unfolded-protein responses. Its mouse data connect microbial dysbiosis to metabolic dysfunction and show that bismuth subsalicylate can improve the phenotype, while also highlighting the need for sex-, species-, and mechanism-specific validation.
-
CSBTA Pharmacokinetics in MASH: Key Study Insights
2026-09-09
The reference study integrates plasma pharmacokinetics, tissue distribution, intracellular accumulation, and enzyme–transporter mechanisms to explain how HFHCD-induced MASH changes the disposition of Corydalis saxicola Bunting total alkaloids. Its findings show why disease state and repeated dosing should be treated as central variables when designing MASLD/MASH pharmacology studies and interpreting exposure variability.
-
25-Hydroxycholesterol Reprograms Immunosuppressive TAMs
2026-09-08
Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that accumulates in lysosomes and drives suppressive tumor-associated macrophage states. The study connects lysosomal lipid sensing to AMPKα–STAT6 signaling, showing that CH25H loss can improve T-cell activity and strengthen anti-PD-1 responses.
-
FITC-Concanavalin A (ConA) Workflow Guide
2026-09-08
FITC-Concanavalin A (ConA) Conjugate is a direct fluorescent lectin reagent for detecting accessible α-D-glucose and α-D-mannose moieties in cell, tissue, and other glycan-containing samples. It is suited to immunofluorescence staining and flow cytometry carbohydrate-probe workflows, but not to non-carbohydrate targets or assays performed outside the specified storage and handling conditions.